<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463655</url>
  </required_header>
  <id_info>
    <org_study_id>AGASA-SP-IPC 2017-004</org_study_id>
    <nct_id>NCT03463655</nct_id>
  </id_info>
  <brief_title>Serum-Ascites Albumin Gradient Analysis in Cancer Patients in Palliative Care</brief_title>
  <acronym>AGASA-SP</acronym>
  <official_title>Serum-Ascites Albumin Gradient Analysis in Cancer Patients in Palliative Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current recommendations do not recommend the concomitant administration of albumin after
      ascites puncture in patients with ascites neoplasia unlike cirrhotic ascites. The etiology of
      ascites in cancer patients is multifactorial, particularly by hepatic invasion that can lead
      to ascites loaded with albumin. Ascites punctures therefore lead to undernutrition, recurrent
      early ascites by decreasing the oncotic pressure by hypo albuminemia and a state of anasarca
      affecting the quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the recommendations, each ascites fluid must be sent for biochemical and
      bacteriological analysis.

      Demonstrate the high gradient proportion (percent only, no threshold of significance
      required). The literature has already validated the importance of supplementing albumen with
      cirrhotic ascites. Demonstrating that some cancer patients have high gradients, this will be
      enough to make the practitioner think to supplement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum-Ascites Albumin Gradient Prevalence</measure>
    <time_frame>3 months</time_frame>
    <description>Elevated Serum-Ascites Albumin Gradient Prevalence in Palliative Cancer Patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metastatic sites</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Metastatic sites of patients with a high gradient.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Solid Cancer in a Palliative Situation With Ascites</condition>
  <arm_group>
    <arm_group_label>solid cancer in a palliative situation with ascites</arm_group_label>
    <description>Patient over the age of 18, followed for a solid cancer in a palliative metastatic situation, having had a puncture of ascites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>cirrhotic albumin</intervention_name>
    <description>Ascites puncture</description>
    <arm_group_label>solid cancer in a palliative situation with ascites</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum albumin</intervention_name>
    <description>blood punctures</description>
    <arm_group_label>solid cancer in a palliative situation with ascites</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All HDJ, UAI, and the 3 medical oncology departments patients who have ascites puncture may
        be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years of age followed for a solid cancer in a palliative metastatic
             situation who had a puncture of ascites.

        Exclusion Criteria:

          -  Minor patient

          -  Known cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Aurélien PROUX</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélien PROUX</last_name>
    <phone>0491227643</phone>
    <email>PROUXA@ipc.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <state>Bouches Du Rhone</state>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique GENRE, MD</last_name>
      <phone>33 4 91 22 37 78</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Carrier P, Jacques J, Debette-Gratien M, Legros R, Sarabi M, Vidal E, Sautereau D, Bezanahary H, Ly KH, Loustaud-Ratti V. [Non-cirrhotic ascites: pathophysiology, diagnosis and etiology]. Rev Med Interne. 2014 Jun;35(6):365-71. doi: 10.1016/j.revmed.2013.12.001. Epub 2014 Jan 6. Review. French.</citation>
    <PMID>24406314</PMID>
  </reference>
  <reference>
    <citation>Guide pratique des soins palliatifs Edition A.P.E.S. (2008)</citation>
  </reference>
  <reference>
    <citation>Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007 May;18(5):945-9. Epub 2007 Feb 13.</citation>
    <PMID>17298959</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>palliative</keyword>
  <keyword>solid tumor</keyword>
  <keyword>ascites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

